Adiponectin Correlates in Malaysians: A Comparison of Metabolic Syndrome and Healthy Respondents

Mohd Aznan Md Aris^{1, 2}, Muhammad Muzaffar Ali Khan Khattak^{2, 3,} , Zamzila Abdullah⁴, Razman Mohd Rus⁵ and And Samsul Draman¹

¹Department of Family Medicine, Kulliyyah of Medicine, International Islamic University Malaysia, International Islamic University, Malaysia, Jalan Sultan Ahmed Shah, Bandar Indera Mahkota Kuantan, Pahang Darul Makmur, MALAYSIA

²Non Communicable Diseases Research Unit, Kulliyyah of Medicine, International Islamic University Malaysia (IIUM) Jalan Sultan Ahmad Shah, Bandar Indera Mahkota, Kuantan, Pahang Darul Makmur; Malaysia.

³Department of Nutrition Sciences, Kulliyyah of Allied Health Sciences, International Islamic University, Malaysia, Jalan Sultan Ahmed Shah, Bandar Indera Mahkota Kuantan, Pahang Darul Makmur, MALAYSIA;International Institute for Halal Research and Training (INHART), Kulliyyah of Engineering, International Islamic University Malaysia, Kuala Lumpur, MALAYSIA

⁴Department of Basic Health Sciences, Kulliyyah of Medicine, Jalan Sultan Ahmed Shah, Bandar Indera Mahkota Kuantan, Pahang Darul Makmur, MALAYSIA

⁵Department of Community Medicine, Kulliyyah of Medicine, Jalan Sultan Ahmed Shah, Bandar Indera Mahkota Kuantan, Pahang Darul Makmur, MALAYSIA

Cite this paper

Mohd Aznan Md Aris, Muhammad Muzaffar Ali Khan Khattak, Zamzila Abdullah, Razman Mohd Rus and And Samsul Draman. Adiponectin Correlates in Malaysians: A Comparison of Metabolic Syndrome and Healthy Respondents. American Journal of Clinical Medicine Research. 2014; 2(6):106-110. doi: 10.12691/AJCMR-2-6-1

Abstract

Several studies have demonstrated that adiponectin has strong association with metabolic syndrome and its factors like obesity, insulin resistance, type 2 diabetes, dyslipidemia and coronary artery disease. A total 152 subjects were registered in this study. Among the respondents 76 were with metabolic syndrome (based on the criteria of the International Diabetes Federation (IDF) world-wide definition) and another 76 matching healthy respondents. The factors which were studied for possible differences and association include central obesity (body mass index (BMI) & waist circumference (WC), hypertension (systolic blood pressure (SBP), diastolic blood pressure (DBP), dyslipidemia (total cholesterol (Tc), high density lipoprotein Cholesterol (HDL-c), low density lipoprotein Cholesterol (LDL-c), Triglyceride (TG) and Adiponectin (AD), fasting plasma glucose and history of smoking. The data collected was statistically analyzed using SPSS statistical software version 12.0. Two tests were performed including paired t-test and Pearson correlation analysis. The collected data revealed some interesting differences for the healthy and metabolic syndrome respondents. There were significant (P<0.01) differences for central obesity and hypertension. There were also significant (P<0.01, P<0.1, P<0.01) differences for TG, HDL and fasting plasma glucose. More importantly, AD concentration was significantly (P<0.05) higher in normal healthy respondents. The AD showed strong negative association (r = - 2.91, P<0.001) with FBG and positive association (r = 2.89, P<0.001) with HDL-c. The present study provides baseline information on the predication of metabolic syndrome in Malaysian population.

Keywords

adiponectin, abdominal obesity, metabolic syndrome, hypertension, dyslipidemia

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report. Circul 106: 3143-32441, 2002.
[2]	Rosario S, Tiziana D C, Christiano A, Salvatore C, Giuseppe L. Hypoadinectinemia: A link between visceral obesity and metabolic syndrome. J Diabetes and Endocrinol 1: 27-35, (2010).
[3]	Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. The Am J Cardiol 83: 25F-29F, 1999.
[4]	Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol and Metab 54: 254-260, 1982.
[5]	Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S.. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabol 36: 54-59, 1987.
[6]	Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, Islam A H, Keno Y, Kobatake T and Nagai Y. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107: 239-246, 1994.
[7]	Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 395: 763-770, 1998.
[8]	Hotmisligli GS, Arner P, Caro JF, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995.
[9]	Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Med 2: 800-803, 1996.
[10]	Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K, Radha V. Association of low adiponectin levels with the metabolic syndrome-the Chennai Urban rural Epidemiology Study. Metabol 54: 476-481, 2005.
[11]	Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin. Endocrinol 61: 75-80, 2004.
[12]	Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a Biomarker of the Metabolic Syndrome. Circ J 68: 975-981, 2004.
[13]	Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, Sugiura K, Kondo T, Murohara T, Toyoshima H.. Comparison of circulating Adiponectin and Proinflammatory markers regarding their association with metabolic syndrome in Japanese Men. Arterioscler Thromb Vasc Biol 26: 871-876, 2006.
[14]	Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Möhlig M, Pfeiffer AF, Luft FC, Sharma AM. Association between adiponectin and mediators of inflammation in obese women. Diabetes 52: 942-947, 2003.
[15]	Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA.. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 86:1930-1935, 2001.
[16]	Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.
[17]	Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory Markers, Adiponectin and Risk of Type 2 Diabetes in the Pima Indian. Diabetes Care 26: 1745-1751, 2003.
[18]	Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-58, 2002.
[19]	Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26: 3226-3229, 2003.
[20]	Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87: 2764-2769, 2002.
[21]	Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141, 2002.
[22]	Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815–3819, 2001.
[23]	Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM. Synthetic peroxisome proliferator-activated receptor-_ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380, 2002.
[24]	Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y.Diet-induced insulin resistance in mice lacking adiponectin/ ACRP30. Nat Med 8:731-737, 2002.
[25]	Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with lipoatrophy and obesity. Nat Med. 7:941-946, 2001.
[26]	Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci 98:2005-2010, 2001.
[27]	State/District Data Bank,Malaysia, Department of Statistics, Malaysia, 2012. statistics.gov.my/portal/download.../Bank_Data_Negeri_Daerah2012.pdf. (Accessed on September 2, 2014).
[28]	Alberti KG, Zimmet P, Shaw J. The metabolic syndrome. A new worldwide definition. Lancet. 366: 1059–1062, 2005.
[29]	Lwanga, S.K and Lemeshow S. Sample size determination in health studies: A practical manual. WHO, Geneva, 1991.
[30]	Gil-Campos M, Canete R, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 23: 963-974, 2004.
[31]	Hotta K, Funahashi T, Arita Y. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscl Thromb Vasc Biol 20: 1595-1599, 2000.
[32]	Rosario S, Tiziana DC, Christiano A, Argano C, Corrao S, Licata G. Hypoadinectinemia: A link between visceral obesity and metabolic syndrome. J Diabetes and Endocrinol 1: 27-35, 2010.
[33]	Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS 580: 2917-2921, 2006.
[34]	Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin as adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circ 102:1296-1301, 2000.
[35]	Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ 68: 975-981, 2004.
[36]	WHO. World Health Organization definition of health. www.who.int/about/definition/en/print.html (Accessed on 30th July, 2014).
[37]	Ford, ES, Chaoyang LI and Guixiang ZHAO. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2:180-193, 2010.
[38]	Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-95, 2002.